KRAS and neoplasm: Alternatively, a preliminary study by Ikeno et al. suggested non-invasive assessment of tumor metabolic activity by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) to be associated with impaired survival in patients with iCCA and KRAS mutations [99].